Neurocrine Biosciences reaches settlement on Ingrezza patent litigation

13 November 2023
neurocrine-big

US neuroscience-focused biopharma Neurocrine Biosciences (Nasdaq: NBIX) today announced that it has resolved all patent litigation related to lawsuits resulting from Abbreviated New Drug Applications (ANDAs) brought by companies seeking approval to market a generic version of Ingrezza (valbenazine) prior to the expiration of applicable Neurocrine patents.

As part of the resolution of these lawsuits, four companies have the right to sell generic versions of Ingrezza in the USA beginning March 1, 2038, or earlier under certain customary circumstances.

"These settlements reinforce our belief in the strength of the Ingrezza intellectual property estate and provide clarity regarding Ingrezza exclusivity. As an innovation-driven biopharmaceutical company, we will continue to develop treatments for under-addressed diseases and rely on a robust patent system to protect that investment in innovation," said Darin Lippoldt, chief legal officer of Neurocrine Biosciences.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology